Mig-2 Attenuates Cisplatin-induced Apoptosis of Human Glioma Cells in Vitro Through AKT/JNK and AKT/p38 Signaling Pathways
Overview
Affiliations
Aim: Mig-2 (also known as Kindlin-2 and FERMT2) is an important regulator of integrin activation and cell-extracellular matrix adhesion, and involved in carcinogenesis and tumor progression. The aim of this study was to investigate the role of mig-2 in cisplatin-induced apoptosis of human glioma cells in vitro.
Methods: The expression of mig-2 was modulated in human glioma H4, HS 683 and U-87 MG cells by transfection with a plasmid carrying mig-2 or mig-2 siRNA. Cisplatin-induced apoptosis was detected using Annexin V/PI staining and flow cytometry, as well as MTS analyses. The expression of apoptosis-related or signaling proteins was examined using Western blotting analysis. H4 cells were transfected with plasmids carrying mig-2 mutants to determine the functional domain of mig-2.
Results: In the 3 glioma cell lines tested, overexpression of mig-2 significantly attenuated cisplatin-induced apoptosis, whereas knock-down of mig-2 potentiated the apoptosis. The mechanisms of action of mig-2 were further addressed in H4 cells: overexpression of mig-2 markedly reduced cleaved caspase-9, caspase-8, caspase-3 and PARP, as well as p-JNK and p-p38, and increased p-AKT in cisplatin-treated H4 cells, whereas mig-2 siRNA reversely changed these apoptosis-related and signaling proteins. Furthermore, pretreatment with JNK inhibitor SP600125 and p38 inhibitor SB203580, or with AKT inhibitor LY294002 abolished the effects of mig-2 on cisplaxtin-induced apoptosis. In H4 cells, GFP-mig-2 F3 plasmid that contained only the F3 subdomain showed the same efficiency in attenuating cisplatin-induced apoptosis, as the mig-2 wild-type vector did, whereas GFP-mig-2 (1-541) plasmid that lacked the F3 subdomain was inactive.
Conclusion: Mig-2 significantly attenuates the antitumor action of cisplatin against human glioma cells in vitro through AKT/JNK and AKT/p38 signaling pathways. The F3 subdomain of mig-2 is necessary and sufficient for this effect.
Zhuo S, Tang C, Yang L, Chen Z, Chen T, Wang K Ann Med. 2023; 55(2):2264325.
PMID: 37795794 PMC: 10557566. DOI: 10.1080/07853890.2023.2264325.
Seo J, Yoon G, Park S, Shim J, Chae J, Jeon Y J Microbiol Biotechnol. 2022; 32(9):1103-1109.
PMID: 36039387 PMC: 9628964. DOI: 10.4014/jmb.2207.07012.
Kindlins as modulators of breast cancer progression.
Plow E, Pluskota E, Bialkowska K J Breast Cancer Res. 2022; 1(2):20-29.
PMID: 35936112 PMC: 9352049.
Zhang G, Wang B, Cheng S, Fan H, Liu S, Zhou B Transl Cancer Res. 2022; 10(7):3491-3506.
PMID: 35116653 PMC: 8799170. DOI: 10.21037/tcr-21-869.
Role of Kindlin-2 in cancer progression and metastasis.
Wang W, Kansakar U, Markovic V, Sossey-Alaoui K Ann Transl Med. 2020; 8(14):901.
PMID: 32793745 PMC: 7396786. DOI: 10.21037/atm.2020.03.64.